Business Context and Reporting Period
This Form 8-K filing by Nephros, Inc. (NEPH) reports a change in executive leadership effective January 28, 2021. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed is a one-time separation payment of $20,000 to the departing Chief Financial Officer.
Material Changes
- Departure: Daniel DAgostino resigned as Chief Financial Officer effective immediately to return to investment banking.
- Appointment: Andrew Astor, the current Chief Executive Officer, was appointed as the new Chief Financial Officer effective immediately.
- Compensation: Mr. Astor will receive no additional compensation for his new role as CFO. Mr. DAgostino will receive a lump sum of $20,000 under a separation agreement.
Outlook, Risks, and Management Commentary
Management commentary is limited to the transition of duties. Mr. Astor has prior experience as the company's CFO (2017–2020) and COO (2018–2020). The separation agreement includes a release of claims and reaffirms restrictive covenants. The full text of the separation agreement is not included in this filing but will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2021.
Investor Verification Checklist
- Verify the terms of the separation agreement with Daniel DAgostino once filed as an exhibit to the Q1 2021 Form 10-Q.
- Confirm the timeline for the appointment of a permanent CFO if Mr. Astor's dual role is intended to be temporary.
- Review the company's most recent Form 10-K or 10-Q for current financial performance, as this 8-K contains no operational financial data.